Blockchain Registration Transaction Record

VolitionRx Expands to Japan with Nu.Q® Discover Assay Distribution Deal

VolitionRx appoints Medical & Biological Laboratories as distributor for Nu.Q® Discover assays in Japan, expanding access to epigenetic biomarker tests for drug developers and researchers in key global market.

This expansion matters because it represents a significant step forward in making advanced epigenetic diagnostics more accessible globally, particularly in Japan's sophisticated healthcare market. Epigenetic testing represents the next frontier in precision medicine, offering earlier and more accurate detection of diseases like cancer and sepsis than traditional methods. By expanding to Japan—a country with one of the world's most advanced healthcare systems and significant pharmaceutical research infrastructure—VolitionRx is positioning its nucleosome-based biomarker assays to potentially accelerate drug development and improve patient outcomes. For patients, this could mean earlier cancer detection when treatments are most effective, and for researchers, it provides another tool to advance personalized medicine approaches. The growing adoption of these assays by nearly 100 clients worldwide suggests they're gaining traction in the scientific community, potentially leading to breakthroughs in how we diagnose and monitor serious diseases.